Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Chapter Taps Into P&G Product Development Capacity

This article was originally published in The Tan Sheet

Executive Summary

Six months after becoming a wholly owned subsidiary of Procter & Gamble, dietary supplement firm New Chapter is taking advantage of its parent company’s resources in innovation, ingredient sourcing, clinical trials and packaging, says New Chapter VP Graham Rigby.

You may also be interested in...



Botanical Supplement Firms Strive For Full-Spectrum Science

Though regulators and standard-setting organizations want firms to identify and standardize their ingredients, botanical supplement makers are moving toward more traditional “full-spectrum” usage of whole herbs. Procter & Gamble subsidiary New Chapter is among the firms focused on whole-food supplements.

Botanical Supplement Firms Strive For Full-Spectrum Science

Though regulators and standard-setting organizations want firms to identify and standardize their ingredients, botanical supplement makers are moving toward more traditional “full-spectrum” usage of whole herbs. Procter & Gamble subsidiary New Chapter is among the firms focused on whole-food supplements.

Reckitt Bids Up Bayer With $1.4 Bil. Schiff Nutrition Offer

Reckitt Benckiser’s $1.4 billion offer to acquire Schiff Nutrition would be 23.5% higher than Bayer’s and more than an 80% premium over Schiff’s share price prior to the Bayer announcement. Gaining Schiff would expand Reckitt’s consumer health business beyond OTC drugs and represent its first supplement foray.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel